Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
| ▸ | AKT1 | P31749 | 4/20 | 0.34 |
| ▸ | AURKA | O14965 | 11/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 11/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932270 | 0.88 | BRAF (0.38) | PARP1BRAFKDM4EHPGD | |
| SCHEMBL9932430 | 0.85 | BRAF (0.38) | BRAFAKT1AURKARPS6KB1AURKB | |
| SCHEMBL9932544 | 0.80 | BRAF (0.39) | PARP1BRAFAKT1AURKARPS6KB1 | |
| SCHEMBL9932401 | 0.79 | BRAF (0.41) | BRAFAKT1AURKARPS6KB1AURKB | |
| SCHEMBL9971077 | 0.78 | BRAF (0.65) | BRAF | |
| SCHEMBL9933084 | 0.76 | BRAF (0.38) | BRAFAKT1AURKARPS6KB1AURKB | |
| SCHEMBL9931498 | 0.75 | BRAF (0.46) | BRAFAURKB | |
| SCHEMBL9932324 | 0.74 | BRAF (0.61) | BRAFPDPK1 | |
| SCHEMBL9932910 | 0.73 | BRAF (0.47) | BRAFAKT1AURKARPS6KB1AURKB | |
| SCHEMBL9932437 | 0.72 | BRAF (0.39) | BRAFAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157453-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157453-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | PARP1 2993/4885BRAF 1/4885AKT1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.